Emergent's Immunoglobulin Fails COVID-19 Trial Day After J&J Vaccine Mix-Up

Emergent's Immunoglobulin Fails COVID-19 Trial Day After J&J Vaccine Mix-Up

Source: 
BioSpace
snippet: 

Gaithersburg, Md.-based Emergent BioSolutions offered an update on its Phase III trial of SARS-CoV-2 Immune Globulin Intravenous (Human) (COVID-HIG) to treat hospitalized patients with COVID-19. Unfortunately, the ITAC trial showed that the addition of the treatment to Gilead Sciences’ remdesivir, did not provide clinical benefit compared to standard of care plus placebo in hospitalized adult COVID-19 patients with symptoms for less than 12 days. No safety issues were raised.